Summit Trail Advisors LLC Acquires New Stake in Insulet Co. (NASDAQ:PODD)

Summit Trail Advisors LLC acquired a new stake in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,882 shares of the medical instruments supplier’s stock, valued at approximately $491,000.

A number of other large investors have also bought and sold shares of the company. CWM LLC grew its stake in shares of Insulet by 3.4% during the 3rd quarter. CWM LLC now owns 3,984 shares of the medical instruments supplier’s stock worth $927,000 after acquiring an additional 132 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in Insulet by 500.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 600 shares of the medical instruments supplier’s stock valued at $139,000 after purchasing an additional 500 shares during the last quarter. Exchange Traded Concepts LLC purchased a new position in shares of Insulet in the third quarter worth about $121,000. Swedbank AB raised its position in shares of Insulet by 3.2% in the third quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier’s stock valued at $4,942,000 after purchasing an additional 655 shares during the period. Finally, Cabot Wealth Management Inc. raised its position in shares of Insulet by 1.7% in the third quarter. Cabot Wealth Management Inc. now owns 15,983 shares of the medical instruments supplier’s stock valued at $3,720,000 after purchasing an additional 262 shares during the period.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $284.26 on Wednesday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The stock has a market cap of $19.94 billion, a price-to-earnings ratio of 48.67, a P/E/G ratio of 3.61 and a beta of 1.23. The stock’s 50-day moving average is $270.94 and its 200 day moving average is $242.89.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PODD. BTIG Research lifted their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Citigroup boosted their price objective on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Finally, Morgan Stanley upped their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $277.13.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.